Combined Epidermal Growth Factor Receptor and Beclin1 Autophagic Protein Expression Analysis Identifies Different Clinical Presentations, Responses to Chemo- and Radiotherapy, and Prognosis in Glioblastoma

Table 1

Distribution of patient in each category, on account of clinical parameters and in each L/H-EGFR and L/H-Beclin1 protein expression group. Significant () correlations with clinical parameters are also given for each EGFR and Beclin1 expression group, and in L-EGFR + H-Beclin1 versus all the other expression groups in regard of both these proteins. Objective Response (OR) was considered Complete Radiological Response plus Partial Radiological Response.

	L-EGFR; pts	H-EGFR; pts	-value
KPS
100–80	43	48
<70	6	20	0.03
NPS
class 1	13	7
class 2	20	21
class 3	10	24
class 4	6	16	0.002
Syncronous Multifocality
Yes	3	16
No	46	52	0.01
Radiological Response
Complete Response	10	9
Partial Response (OR)	17 (27)	9 (18)
Stable Disease	10	15	0.013
Progressive Disease	12	35
	H-Beclin1; pts	L-Beclin1; pts	-value
KPS
100–80	51	40
<70	7	19	0.009
Radiological Response
Complete Response	14	5
Partial sdResponse (OR)	19 (33)	7 (12)
Stable Disease	14	11	0.009
Progressive Disease	11	36
	L-EGFR + H-Beclin1	All the other GBs	-value
KPS
100–80	24	67
<70	0	26	0.03
NPS
class 1	9	11
class 2	9	32
class 3	5	29
class 4	1	21	0.002
Syncronous Multifocality
Yes	0	19
No	24	74	0.002
Radiological Response
Complete Response	13	6
Partial Response (OR)	8 (21)	18 (24)
Stable Disease	3	22
Progressive Disease	0	47	0.013